Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, has entered a strategic supply agreement with Blossom Genetics. The agreement outlines plans to bring Colombian medical cannabis to the German market. The collaboration will specifically include Chemmy Jones and Northern Lights, two highly sought-after exotic strains. According to the announcement, the agreement supports Flora Growth’s commitment to meet Germany’s growing demand for high-quality medical cannabis; the country legalized the substance earlier this year.
“This supply agreement with Blossom Genetics is a pivotal step in our efforts to expand Flora’s global presence and provide top-tier cannabis products to Germany,” said Flora Growth chair and CEO Clifford Starke in the press release. “The demand for medical cannabis has surged since legalization, and we are confident that the strains we will bring to the market, will resonate with patients and healthcare providers alike.”
To view the full press release, visit https://ibn.fm/5vHcy
About Flora Growth Corp.
Flora Growth is on a mission to become the leading NASDAQ small-cap international cannabis company. It is a cannabis-focused, consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world. For more information about the company, please visit www.FloraGrowth.com.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
